116 related articles for article (PubMed ID: 29520905)
1. Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir.
Chia XX; Cherepanoff S; Danta M; Furlong T
Nephrology (Carlton); 2018 Apr; 23(4):379-380. PubMed ID: 29520905
[No Abstract] [Full Text] [Related]
2. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
Huang H; Tang H; Deng H; Shen J; Zhou Q; Xie W; Wu J; Chen J
Transpl Infect Dis; 2019 Feb; 21(1):e13018. PubMed ID: 30369001
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis.
Pescitelli L; Lazzeri L; Tripo L; Ricceri F; Di Cesare A; Prignano F
Dermatol Ther; 2018 Jul; 31(4):e12614. PubMed ID: 29708289
[TBL] [Abstract][Full Text] [Related]
5. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness and safety of sofosbuvir+daclatasvir in the treatment of chronic hepatitis C virus infection in Yan'an, Shaanxi].
Gao XH; Jing P
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):457-459. PubMed ID: 31357763
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
Xue Y; Zhang LX; Wang L; Li T; Qu YD; Liu F
World J Gastroenterol; 2017 Aug; 23(32):5969-5976. PubMed ID: 28932089
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir and daclatasvir.
Hessel MH; Cohen AF; Rissmann R
Br J Clin Pharmacol; 2016 Sep; 82(3):878-9. PubMed ID: 27198488
[No Abstract] [Full Text] [Related]
9. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
[TBL] [Abstract][Full Text] [Related]
10. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
[TBL] [Abstract][Full Text] [Related]
11. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.
Sundaram V; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2016; 10(1):13-20. PubMed ID: 26560449
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay.
Virlogeux V; Choupeaux L; Pradat P; Maynard M; Bailly F; Scholtès C; Gagnieu MC; Zoulim F
Dig Liver Dis; 2016 Nov; 48(11):1351-1356. PubMed ID: 27498075
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
Schrezenmeier E; Hoffmann F; Jaeger C; Schrezenmeier J; Lisec J; Glander P; Algharably E; Kreutz R; Budde K; Duerr M; Halleck F
Ther Drug Monit; 2019 Feb; 41(1):53-58. PubMed ID: 30422962
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease.
Vionnet J; Saouli AC; Pascual M; Stucker F; Decosterd LA; Moradpour D; Chtioui H
J Hepatol; 2016 Nov; 65(5):1063-1065. PubMed ID: 27469899
[No Abstract] [Full Text] [Related]
16. Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir.
Ozaras R; Mete B; Yemisen M; Balkan II; Alkan M; Tabak F
J Gastrointestin Liver Dis; 2015 Sep; 24(3):393-4. PubMed ID: 26405716
[No Abstract] [Full Text] [Related]
17. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
[TBL] [Abstract][Full Text] [Related]
18. Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients.
Ghazy AA; Osman EM; Rashwan EA; Gaballah AH; Mostafa H; Tawfik S
J Med Virol; 2019 Dec; 91(12):2166-2173. PubMed ID: 31368531
[TBL] [Abstract][Full Text] [Related]
19. Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
Nafisi S; Roy S; Gish R; Manch R; Kohli A
Expert Rev Anti Infect Ther; 2016; 14(1):41-56. PubMed ID: 26654939
[TBL] [Abstract][Full Text] [Related]
20. Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.
Gevers TJ; Burger D; Schipper-Reintjes E; Kooistra MP; Richter C
Neth J Med; 2016 Jun; 74(5):225-7. PubMed ID: 27323683
[No Abstract] [Full Text] [Related]
[Next] [New Search]
